endTB aims to find shorter, less toxic and more effective treatments for ‘multidrug-resistant TB’ (MDR-TB) through:

  • access to new drugs
  • two clinical trials
  • advocacy at national and global levels.

Covering 17 countries, the project is a partnership between Partners In Health, Médecins Sans Frontières, Interactive Research & Development and financial partner UNITAID.

Watch the two-minute animation


You can contact us, or follow us on Twitter.

New TB drugs are safe, effective alternatives

Patient holding his medication, he takes up to 26 pills a day to treat XDR-TB. Here he holds his morning selection, which includes delamanid, one of the newest DR-TB drugs, which he is taking for the first time today.


13 July 2018

New interim findings from endTB indicate bedaquiline and delamanid could benefit many more patients.

Read more

First endTB clinical trial participant completed follow-up

First endTB clinical trial participant completed follow-up


22 March 2019

In March 2019, the endTB clinical trial celebrated a major milestone: the first participant completed participation in the trial. 

Read more